Background: Acinetobacter baumannii, an important nosocominal pathogen, causes various human infections like meningitis, bacteremia and pneumonia. The aim of this study was to produce nanobodies derived from camel heavy chain antibodies (HcAb) against a conserved region of the biofilm associated protein (Bap) of A. baumannii, by phage display technique.
Introduction
Acinetobacter spp. are gram-negative, non-motile, aerobic, nonfermenting bacteria. 1 Acinetobacter baumannii, an important nosocomial pathogen, causes various human infections, such as meningitis, bacteremia, pneumonia and urinary tract infections. [2] [3] [4] Its remarkable resistance to a wide range of antibiotics has made the treatment of infections very difficult. The mortality rate of infected patients is 43% and in some countries this rate has risen to 75%. 5, 6 Worldwide reports of multidrug-resistant (MDR) strains of A. baumannii among hospitalized patients are increasing. 7 It is hypothesized that the ability of A. baumannii to resist antimicrobial stressors, antibiotics or cleaning is due to its ability to form biofilms. 8 Studies suggest that a positive relationship exists between A. baumannii's MDR and biofilm formation. 9 Biofilm-associated protein (Bap), a surface protein with a very high molecular mass and central tandem repetitions, is associated with bacterium virulence and drug resistance. 10 This protein with 8620 amino acids is one of the largest proteins identified. It is one of the most acidic proteins with an isoelectric point of about 3. 11 Bap is the surface structure involved in adherence of A. baumannii to both normal human bronchial epithelial cells and human neonatal keratinocytes. 12 Bioinformatics tools have identified a core domain of seven repeat modules; namely, A to G, of which D, B, C and A are predominant. Because of their three-dimensional structure and antigenic properties, they are nominated as appropriate candidates for vaccination and antibody production. In a previous study we demonstrated that four regions of Bap from A. baumannii were effective antigens. All regions were predicted to be conserved and functional in the native protein. 13 Previous studies have reported high antibody titers in mice after immunization with the conserved region of Bap construct-II consisting of 371 amino acids.
14 Some of the main concerns in A. baumannii infection include the fast growing populations of MDR strains of the bacterium, its remarkable survival ability in nosocominal environments, and the time consuming and expensive procedures used for its identification. 15 A previous study 14 proved the immunogenicity of A. baumannii Bap, therefore, in this study, we attempted to produce a recombinant nanobody derived from camel heavy chain antibodies against the dominant antigenic domains of this protein, using the phage display technique. Unlike the classical form, the camel heavy chain antibody is free of light chains and possesses an antigen binding domain called VHH or nanobody. These nanobodies are small in size with a 2.5 nm diameter and they are 4 nm length. They allow penetration into tissues and have a high homology with human VH. 16 The role of antibodies in the diagnosis and treatment of human diseases and the trend of increasing bacterial drug resistance necessitates novel approaches to these issues. Similarities of VHH and human VH can be exploited in immunotherapy and, to this effect, we aimed to express and produce nanobodies against Bap.
Materials and methods

Preparation of antigen and camel immunization
In our previous study a pET28a vector carrying the recombinant Bap gene was constructed.
14 Transformed Escherichia coli BL21 cells grown in Lysogeny broth (LB) medium to an OD 600 of 0.6 were induced with 1 mM IPTG. After 4 hours of induction at 378C, the cells were collected by centrifugation at 5000×g for 10 min. The cell pellet was resuspended in buffer B (NaH 2 PO 4 100 mM, Tris 10 mM, urea 8 M, pH 8) and sonicated using a sonicator equipped with a microtip. After 2 hours incubation at 378C the lysate was centrifuged at 12 000×g for 20 min at 48C to pellet the cellular debris. The supernatant was applied to a Ni-NTA agarose affinity column (Bangalore Genei, Bangalore, India). The column was washed stepwise with buffers of different pH. Buffer E (denaturing elution buffer, pH4.5) was used to elute the Bap recombinant subunit protein. All buffer solutions contained 8 M urea. The protein was analyzed by 10% SDS-PAGE. Sequential dialysis was carried out against phosphate buffered saline (PBS) (pH7.4) containing descending concentrations of urea from 6, 4 to 2 M, respectively, and finally with PBS only. A 2-year old male camel (Camelus dromedaries) was immunized by five subcutaneous and intramuscular injections of the recombinant Bap subunit at 14 day intervals. For the first injection, Freund's complete adjuvant (Razi institute, Karaj, Iran) was used. Subsequent booster injections were administered with an equal volume of Freund's incomplete adjuvant. All procedures and ethical issues were followed in compliance with relevant laws and institutional guidelines of Shahed University. Sera were collected 1 week after each booster injection and the level of antibody production was measured by indirect ELISA.
For the ELISA, a 96-well microplate (JET BIO FIL, Canada) was coated with 10 mg/ml of the purified Bap recombinant protein per well and incubated at 48C overnight. After washing with PBS-T (PBS 0.05% Tween-20), the wells were blocked with 150 ml of 5% skim milk in PBS-T and incubated for 1 hour at 378C. After washing with PBS-T, 100 ml from various dilutions of the sera were added to each well and incubated for 1 hour at 378C. Wells were then washed several times with PBS-T and 100 ml of 1/16 000 dilution of rabbit anti-camel antibody in PBS-T was added to each well, and the microplate incubated for one hour at 378C. The wells were washed with PBS-T and 100 ml of horseradish peroxidase (HRP) conjugated mouse anti-rabbit antibody (Abcam, Cambridge, UK) was added to each well at a final concentration of 1/5000 and incubated at 378C for 1 hour. After washing the wells, 100 ml/well of tetramethylbenzidine (TMB) (Bangalore, Bangalore Genei, India) was used as substrate buffer. After incubation at 378C for 15 min, the reaction was stopped with the addition of 100 ml of 3N H 2 SO 4 per well and an optical density (OD) was measured at 450 nm.
Lymphocyte purification
EDTA (2 mg/ml) was added to blood samples to prevent blood clotting. Lymphocytes were purified with ficoll gradients at a 2 : 1 ratio and were then dissolved in PBS. Aliquots of 10 8 cells were stored at 2708C in RNAase-free microtubes.
Library construction
Total RNA was extracted from the isolated lymphocytes using the Pure RNA Isolation Kit (Roche, Wisconsin, USA). Oligo dT primers were used to produce cDNA (Fermentas, Germany GmbH). Nested PCR was used to isolate and amplify VHH coding fragments. cDNA served as a template in the first PCR. The regions between Framework 1 and CH2 were amplified with two sets of specific primers:
. Fragments produced from the heavy chain antibody (600 and 700 bp) were purified from the agarose gel using the Bioneer accuperep gel purification kit, and used as a template for a second PCR. VHH was amplified using the following specific degenerated primers:
Fr4-SfiI (5
. VHH genes were purified from the agarose gel (Bioneer, Munpyeong-dong, South Korea), and cloned into sfiI digested pComb3x phagemid vector. Recombinant phagemids were transformed into XL1-Blue E. coli cells by electroporation (Gene pulser Xcell, Bio-Rad, California, USA). In order to determine the library size, 10 ml of transformed bacteria were subcultured on LB-ampicillin (80 mg/ml) agar plates.
Panning of VHH library
VHH nanobodies were displayed on phages after infecting the transformed bacteria with M13K07 helper phage (AmershamPharmacia-Biotech, Vienna, Austria). Briefly, the phage library was grown in 300 ml of super broth (SB) medium containing 80 mg/ml ampicillin. Bacteria at mid-log phase were infected with 3 ml of M13K07 helper phage with 10 11 pfu/ml. Bacteria were then incubated for 30 min without shaking and then for another 30 min with vigorous shaking at 378C. Kanamycin was added to the culture to reach 70 mg/ml and then incubated for 16 hours at 378C and 250 rpm. The culture was centrifuged for 20 min at 4000×g at 48C. For purification of the phage particles, 20% (v/v) of PEG/NaCl solution (16.7% polyethylene glycol [PEG] and 19.49% NaCl) was add to the supernatant and incubated for 60 min on ice. After centrifugation for 15 min at 12 000×g at 48C, the pellet was resuspended in 2-3 ml of TBS (150 mM NaCl and 50 mM Tris base, pH7.2) containing 1% bovine serum albumin (BSA). The suspension was centrifuged for 5 min at 12 000×g and phage-containing supernatant was collected for biopanning.
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Bap specific VHHs were propagated by six rounds of biopanning. Microplate wells were coated with Bap recombinant protein in Tris buffered saline (TBS) at 48C overnight. After the wells were blocked with PBS with 3% BSA, 100 ml of the concentrated phage library was added to the well. To ensure isolation of high affinity nanobodies the number of washes was increased after each panning round and the amount of tween-20 in washing buffer was increased from 0.1% to 0.5%. The bound phages were finally eluted with 0.2 M glycine-HCl, pH2.2. The eluted phages were neutralized in 1 M Tris buffer at pH9. Half of the eluted phages were used to infect E. coli XL1-Blue at mid-log phase and the other half was used for propagation and conducting polyclonal phage ELISA.
Screening and isolation appropriate clones
Polyclonal phage ELISA was used to assess the panning process. To coat the microplate wells, 100 ml of Bap protein in TBS at 10 mg/ml concentration was used and the plate was incubated for 16 hours at 48C. The wells were blocked with 150 ml of 5% skim milk in PBS-T for 1 hour. After washing the wells with PBS-T, the purified phages from each round of panning were added. After washing, 100 ml anti-M13 monoclonal antibody conjugated to HRP (Amersham, Pharmacia-Biotech, Vienna, Austria) was added at a final concentration of 1/8000 and the microplate was incubated for 1 hour at 378C. TMB substrate was added after washing and the reaction was stopped with H 2 SO 4 (3N) after 15 min. Color intensity was measured at 450 nm using an ELISA reader. Colonies were randomly selected from the fifth round of panning and screened for the VHH gene by PCR. Phage particles from each clone were propagated separately as described in 'Panning of VHH library'. The affinity of the different VHH clones towards the Bap protein was assessed using phage-ELISA, as described above.
Expression of VHH fragment
The C20 clone that scored the highest OD reading in the monoclonal phage-ELISA was selected for expression of soluble VHH. The phagemid was extracted and then transformed into E. coli Top10F'. Expression was induced with 1 mM IPTG (Bangalore Genei, India) at an OD 600 of 0.5 and at 288C. Cell pellets were collected by centrifugation at 5000×g at 48C for 20 min. Pellets were sonicated in lysis buffer containing protease inhibitor phenyl methyl sulfonyl fluoride (PMSF) at a final concentration of 1 mM. After centrifugation, the supernatant was collected and the production of nanobodies was analyzed on 14% SDS-PAGE.
Expression of nanobody in E. coli BL21 (DE3)
For a higher expression level, selected nanobodies were subcloned into a pET-28a expression vector using the following pair of PCR primers: Fr4-EcoRI 5
′ -ACTTCAGAATTCGAGGTGCAGCTGSWGSAKTCK G-3 ′ and Fr1-HindIII 5 ′ -ACTACAAAGCTTTTAGGAGACGGTGACCW GGGTC-3, ′ containing EcoRI and HindIII restriction sites, respectively. The construct was transformed into E. coli BL21 (DE3). Expression was adjusted at different temperatures and IPTG concentrations. VHH expression was then induced with 1 mM IPTG for 8 hours at 378C when OD 600 reached 0.5. Bacteria were harvested by centrifugation at 4000×g at 48C for 10 min and then resuspended in lysis buffer. The cells were sonicated on ice. After centrifugation, the clear supernatant was loaded onto a Ni-nitriloacetic acid (Ni-NTA) agarose column (Qiagen, Valencia, CA), and the bound proteins were eluted with buffer E (urea 8 M, pH4.5).
SDS-PAGE and Western blotting
Purification of the nanobodies were examined on 14% SDS-PAGE under reducing conditions. For Western blotting, a gel was run at a constant voltage (100 V) for 1 hour and then protein bands were transferred to nitrocellulose membrane using the Bio-Rad Mini Protein Tetra system (California, USA).The nitrocellulose membrane was blocked with 5% skim milk in PBS-T for 16 hours at 48C. The membrane was then washed and detection was performed using HRP conjugated anti-His Tag antibody (1/5000) (Abcam, Cambridge, UK) and diaminobenzidine (DAB) (Bangalore Genei, India) as substrates.
Sequencing
The VHH sequence of C20-pET28a clone was performed with T7 terminator universal primers and the result was blasted against the National Center for Biotechnology Information (NCBI) database.
Cross-reactions
A. baumannii (ATCC 19606) and 60 biofilm forming strains of the same bacterium isolated and clinically identified from patients admitted in hospitals in Tehran were used as tests. E.coli (ATCC 25922), Staphylococcus aureus (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853) and their clinical isolates were used as negative controls. The above bacteria were cultured in LB broth. The bacterial cells were harvested, washed three times with coating buffer (0.1 M Na 2 CO 3 , 0.1 M NaHCO 3 , pH9.5) and resuspended at 1.5 × 10 8 cells ml 21 . For ELISA, 100 ml of each bacteria was added into the wells of polystyrene flat-bottom 96-well microtiter plates and coated overnight at 48C. The plates were then dried with a hair dryer and washed three times with phosphate-buffered saline (0.05 M, pH7.4) containing 0.02% sodium azide and 0.05% (vol/vol) Tween20 (PBST). The remaining binding sites on the plates were blocked with PBS containing 10% (w/v) skimmed milk for 1 hour at 378C. Equal volumes of the nanobody were added and incubated for 2 hours at 378C. After washing the plate three times, 100 ml of anti His-Tag antibody peroxidase conjugate (Qiagen, Hilden, Germany) diluted to 1 : 100 000 in PBS-T was added and incubated for 1 hour at 378C. The wells were then washed three times and 100 ml per well of the TMB substrate was added. The reaction was stopped by the addition of 100 ml 3N H 2 SO 4 per well.
Binding specificity
In order to evaluate the specificity of the nanobodies, 20 mg of various antigens were produced and standardized in our biotechnology laboratory, including: Bap antigen, recombinant C-terminal fragment of Helicobacter pylori UreC protein, BSA, Vibrio cholerae lipopolysaccharide, Salmonella enterica serotype Typhimurium lipopolysaccharide and Clostridium botulinum neurotoxin type E. They were incubated in microplate wells for 16 hours at 48C and ELISA was performed as described under Cross-reactions.
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Binding affinity of nanobody to Bap
Affinity of the purified nanobodies was determined by ELISA. Wells of a microplate were coated with 100 ml of 1.25, 2.5, 5 and 10 mg/ ml concentrations of Bap. After the washing and blocking steps, 100 ml of the nanobody was added at concentrations of 0, 1.25, 2.5, 5 and 10 mg/ml. HRP-conjugated with anti-His antibody was added and the immunoreactivity was developed using the TMB substrate. The reaction was stopped with 3N H 2 SO 4 and an OD measured at 450 nm.
In vivo neutralization assay
The LD 50 of biofilm producing A. baumannii was estimated by intraperitoneal injection of live A. baumannii at log phase, at concentrations ranging from 10 4 to 10 10 bacteria/ml in male BALB/C mice. The animals were monitored for mortality in the first 72 hours after inoculation. In vivo neutralization was assayed by mixing 20 mg of nanobodies with various concentrations of live A. baumannii suspensions, within a range of 2, 3, 4, 5, 6, 7, 8 and 9 LD 50 and incubating for 1 hour at 378C. The mixtures were brought to 100 ml with PBS and injected intraperitoneally to groups of four mice per bacterial dose. The above procedure was also carried out for control groups where PBS was added instead of the nanobody. The mice groups were monitored for 72 hours and the time of death was recorded.
Results
Camel immune response
Sera from non-immune and immune camels were assessed by indirect ELISA using the Bap recombinant protein as an antigen. The antibody titer of the immune serum against Bap was highest after the fifth injection (Figure 1 ).
Lymphocytes purification and RNA purification
Lymphocytes were isolated from uncoagulated blood of an immunized camel. Total RNA were purified from 10 6 cells. cDNA was prepared from purified RNA by oligo dT primers.
VHH amplification and library construction
The cDNA was used as template to amplify the coding sequence of nanobodies using nested PCR. Due to the lack of CH1 domain in the heavy-chain antibodies, the VHH coding sequences can be separated from the classical antibodies by nested PCR. In the first PCR, CALL001, CALL002, A4 and A6 primers amplified the regions between CH2 and framework 1 of variable domain of both the classical and heavy-chain antibodies. The amplified fragments of the classical antibodies contained the CH1 region and had a 900 bp length whereas the fragments of heavy chain antibody which lacked the CH1 domain were smaller. In the second PCR, the VHH fragments (400 bp) were generated with specific primers which attached to framework 1 and framework 4 and amplified the variable region. A nanobody library was prepared with 4.8× 10 6 members. Phages binding to the recombinant Bap were selected by six consecutive rounds of biopanning against Bap. After each round of panning, the amount of Tween-20 in TBS-T and washing cycles was increased from 0.1% to 0.5%, in order to isolate the high affinity bound phages.
The fifth round of panning showed the highest immunoactivity in the polyclonal phage-ELISA (Figure 2 ). In the monoclonal phage-ELISA, 20 clones from the fifth round of panning that bound strongly to the Bap recombinant protein and showed minimal affinity towards the control protein (BSA), were screened. From these 20 clones, C20 clone had the highest OD in ELISA and was chosen for further characterization (Figure 3) .
The expressed nanobody in E. coli BL21 (DE3) was purified using a IMAC column (Sigma-Aldrich, Missouri, USA). A single band of the purified protein is shown on SDS-PAGE (Figure 4) . Expression of nanobody was also confirmed by a Western blot assay ( Figure 5 ). The data obtained from the sequencing alignment using NCBI BLAST tools for homologous genomic sequences showed high homology of at least 80% with VHH sequence of camelus dromedaries.
Cross reactivity of the nanobody
The adhesion of the nanobody to A. baumannii (ATCC 19606) and its clinical isolates was higher and more specific than its adhesion to E. coli (ATCC 25922), S. aureus (ATCC 25922), P. aeruginosa (ATCC 
Nanobody affinity determination
The affinity of the purified nanobody measured by ELISA was at 3.8 ×10 8 M
21
.
In vivo neutralization assay
The LD 50 of A. baumannii was estimated as 5 × 10 8 colony-forming unit (CFU). The neutralizing capacity of the purified nanobody against A. baumannii was monitored in test animals. A 50% survival rate was recorded in the test group at seven fold LD 50 as compared to control group. At six fold, LD 50 of 100% survival, with no signs of infection, was recorded.
Discussion
Due to the prevalence of antibiotic-resistant A. baumannii, the high cost of treatment and the risk of relapses, there is a demand for the development of new approaches in the treatment of A. baumannii related diseases. 17 The attachment of antibodies to Bap might inhibit the adhesion of bacterium and play a critical role in the suppression biofilm formation. This inhibition could be explained by conformational changes in the native Bap, while there are sufficient evidence indicating that antigen-antibody interactions can significantly change the molecular conformation of proteins. 18, 19 These findings indicate that the Bap subunit is present on the cellular envelope. Nanobodies have had successful applications in diagnosis and treatment of a variety of epidemic causing pathogens. 20 The variable domain of the camel heavy chain antibody has phenomenal features such as a small-size, high stability and affinity and low immunogenicity. These characteristics have made them suitable for biotechnological applications. 21, 22 The protective effect of Bap-B subunit (371 amino acids) in mice has been reviewed and approved.
14 In this study we used the recombinant construct B of Bap. We describe the successful isolation and cloning of a single domain VHH (nanobody) gene from immunized dromedaries library, followed by soluble expression and characterization of the nanobody. To our knowledge, . 23 In our study, the affinity of the nanobodies against recombinant Bap protein was 3.8× 10 28 M/L. Our data indicate that 20 mg of anti-Bap nanobody can effectively neutralize sixfold LD 50 of A. baumannii in Intraperitoneal injection in mice. The data strongly support the specificity and affinity of the VHH towards the Bap portion. In addition, the small size of VHHs makes its diffusion easier in the dense biofilm layer of bacteria. These characteristics render the produced VHH an appropriate tool for detection or therapeutic purposes. Although application of VHH in its current form is not suitable for therapeutic purposes and would need human IgG FC domain to induce phagocytosis, the overall characteristics of the produced VHH makes it a good candidate for such applications.
Conclusions
The unique features of VHHs make them appropriate tools in identification and therapeutic purposes. Our anti-Bap VHH shares these characteristics and has the ability to neutralize A. baumannii infection as shown in the in-vivo challenge. More attention should be paid to the use of this nanobody as a diagnostic tool for quick detection or treatment of A. baumannii infections.
